0000899243-20-014618.txt : 20200529 0000899243-20-014618.hdr.sgml : 20200529 20200529191716 ACCESSION NUMBER: 0000899243-20-014618 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200527 FILED AS OF DATE: 20200529 DATE AS OF CHANGE: 20200529 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HAUMANN BRETT K CENTRAL INDEX KEY: 0001607733 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 20930307 MAIL ADDRESS: STREET 1: 901 GATEWAY BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-27 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001607733 HAUMANN BRETT K AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 1 0 0 0 Common Stock, $0.0001 par value 2020-05-27 4 A 0 13313 0.00 A 19563 D Stock Option (right to buy) 17.11 2020-05-27 4 A 0 25453 0.00 A 2030-05-26 Common Stock 25453 25453 D These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 1/3rd of the RSUs on each anniversary of the grant date, assuming continuous service as a director until each such vesting date. The shares subject to the option will vest and become exercisable as to 1/36th of the shares subject to the option on each monthly anniversary of the grant date, assuming continuous service as a director until each such vesting date. /s/ Douglas T. Sheehy, as Attorney-in-Fact for Brett K. Haumann 2020-05-29